Hyloris Pharmaceuticals Sa · EURONEXT:HYL
Hyloris Pharmaceuticals Sa — Investor Presentation (November 2022)
13 slides from Hyloris Pharmaceuticals Sa's investor presentation, Nov 22, 2022
Slide 1: New Product Candidate – HY-083
Reformulating the Future New Product Candidate – HY-083 22 November 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presenta
Slide 3: Rethinking, Reinventing, Optimising Existing Medications
Rethinking, Reinventing, Optimising Existing Medications To improve overall therapy outcomes REFORMULATING Changing dose and/or route of administration REPURPOSING/ New therapeutic uses REPOSITIONING For the benefit of patients, physicians, payors 2
Slide 4: To Drive Continuous Growth and Create Shareholders’ Value
To Drive Continuous Growth and Create Shareholders’ Value Acquisition and in-licensing of product Continuously growing diversified product candidates based on portfolio characterised by Clear scientific and medical rationale based on physicians’input Fast market adoption Approved, well-known molecul
Slide 5: Broad, Innovative Portfolio: Expand to ~30 Assets before 2025
Broad, Innovative Portfolio*: Expand to ~30 Assets before 2025 Route of Formulation and Clinical Regulatory Target Product Indication Administration Manufacturing Development Filing Market CARDIOVASCULAR (CV) PORTFOLIO Up to 7 years Sotalol IV IV Atrial fibrillation Launched in U.S./partnered with A
Slide 6: Product Candidate HY-083
Product Candidate HY-083 Nasal Spray in the treatment of Idiopatic Rhinitis 5
Slide 7: Disease overview
Disease overview ” Chronic rhinitis is best defined by the long term ” presence of two or more of the three following Idiopathic rhinitis is chronic rhinitis with no nasal symptoms: sneezing, runny nose, stuffy identifiable cause, and thus an absence of nose. preferred treatment: trial and error. It
Slide 8: Diagnosis and treatment pathway
Diagnosis and treatment pathway Trial and error approach leads to unnecessary surgery Non-Allergic Infectious Rhinitis Allergic Rhinitis Non-infectious Rhinitis Presentation Discolored secretions Positive skin-Prick-Test No sign of sensitization Crusting Specific IgE in serum Patient Geriatric ident
Slide 9: Patient population and addressable market
Patient population and addressable market of the population is suffering ~35% from Chronic Rhinitis Infectious rhinitis Allergic rhinitis 25-50% Non-allergic Rhinitis Other causes Addressable market Idiopathic rhinitis Inflammatory rhinitis Gustatory, drug-induced, ... 7% of the population 50-70% ~1
Slide 10: Rationale for HY-083 and unmet need
Rationale for HY-083 and unmet need ” Patients are typically subjected to multiple rounds of treatment failures that lead to frustration towards seeking medical care and medication use. Children at risk for HY-083 aims to provide significant improvement and Significant increase of permanent facial i
Slide 11: Potential Game Changer, Geared for Growth
Potential Game Changer, Geared for Growth MULTIPLE SHOTS ON GOAL COMMERCIAL PORTFOLIO ≤ 7 years to market 2 patented products with partners ≤ €7 million average cost to market Addressing unmet needs Lower risk as we start from existing drugs Build U.S. commercial team 151 Innovative, patented, value
Slide 12: Anticipated Value Inflection Milestones in the next 12 months
Anticipated Value Inflection Milestones in the next 12 months Clinical Regulatory Commercial • Starting pivotal PK clinical trial for • Commercial partnership(s) Dofetilide IV and HY-029 • Continued roll-out of Maxigesic® IV and Sotalol IV • Starting Phase 2 clinical trial for • Atomoxetine: impleme
Slide 13: Q&A
Q&A \ 12
Hyloris Pharmaceuticals — Investor Presentation (November 2022) on 6ix